Introduction
In human hepatocellular carcinoma (HCC), production of transforming growth factor (TGF)-b, which is a potent growth inhibitor for hepatocytes, is often increased (Ito et al., 1991) . Therefore, obtaining the resistance to growth inhibitory effects caused by the autocrine TGF-b signal in HCC has been thought to be one of the important factors in malignant transformation (Abou-Shady et al., 1999; de Caestecker et al., 2000) . Components of TGF-b signaling pathway are mutated or silenced in some cancers, including colon and pancreatic cancers (Massague, 2000) . However, mutations of Smad2, Smad4, or TGF-b type II receptor in HCC tissues appear to be rare (Furuta et al., 1999; Kawate et al., 1999; Yakicier et al., 1999) , and TGF-b1-Smad signaling pathways are not impaired in many hepatoma cell lines (Ijichi et al., 2001) . These results suggest that pathways not involving mutations to Smads or TGF-b receptors may be responsible for resistance to the antiproliferative effect of TGF-b1 in HCC.
c-Src, a cellular homologue of the Rous sarcoma virus-transforming gene, viral src (v-src), has been associated with malignant transformation (Jove et al., 1987) . There are many reports that c-Src protein expression and/or activity is elevated in epithelial cancers, or cell lines derived from these, and there is often an association between c-Src expression and stage of disease or malignant potential (Biscardi et al., 1999) . Activation of c-Src in HCC is highly correlated with the indices of early stage phenotype (Ito et al., 2001) . Csk, the kinase that phosphorylates tyr-527 and inactivates cSrc, is reduced in HCC as compared to normal liver tissue, and this low Csk expression correlates with enhanced c-Src activity (Masaki et al., 1999) . However, the underlying mechanisms by which c-Src contributes to malignant transformation of hepatocytes and HCC progression remain to be determined. Furthermore, neither the regulation of c-Src activity nor its role in TGF-b1-induced apoptosis is largely unknown. Using FaO hepatoma cells, which are highly sensitive to TGFb1 (Choi et al., 1998 (Choi et al., , 1999 Park et al., 2002) , the present study demonstrates that c-Src is transiently activated in response to TGF-b1 but is ultimately degraded by caspases, possibly contributing to irreversible cell death. On the other hand, overexpression of constitutively active (CA) c-Src conferred resistance to TGF-b1-induced apoptosis. Furthermore, in many human HCC cells resistant to TGF-b1, enhanced c-Src activities were observed. On the basis of these results, we hypothesize that in the early stages of HCC activated c-Src may provide a protection mechanism from the apoptotic effects of TGF-b1, thereby contributing to the progression to malignancy.
Results

c-Src is degraded by caspases after transient activation during TGF-b1-induced apoptosis
FaO cells were incubated with 5 ng/ml TGF-b1 then studied for signs of apoptosis. The terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay indicating DNA fragmentation showed that about 49% of cells were apoptotic after exposure to TGF-b1 for 24 h (Figure 1a) . We investigated how c-Src activity is regulated during TGF-b1-induced apoptosis. Western blotting analysis using an antibody specific for autophosphorylated (active) c-Src showed that its phosphorylation in response to TGF-b1, peaked at 8 h, and then significantly decreased (Figure 1b) . We further examined whether these changes in c-Src activity during TGF-b1-induced apoptosis were due to an alteration in protein level. Western blot analysis using anti-c-Src monoclonal antibody GD11, which recognizes a region of c-Src bounded by amino-acid residues 82-169 (Parson et al., 1984) , showed c-Src protein levels did not alter by 8 h, but after 12 h it appeared c-Src was cleaved to generate an approximately 55 kDa fragment (Figure 1c ). This 55 kDa fragment was not detected by anti-Src antibody Src 2 Ab, which recognizes the carboxy terminus. These results indicate that c-Src is cleaved in the carboxy terminal region during TGF-b1-induced apoptosis. To investigate if caspases or other proteases were involved in c-Src cleavage, FaO cells were treated with TGF-b1 in the presence of specific inhibitors of proteases. TGF-b1-induced c-Src cleavage and apoptotic cell death were both significantly reduced by z-VAD-fmk, a specific inhibitor of pan-caspases (Figure 1d ). Addition of inhibitors of single caspase(s) did not block c-Src cleavage completely, although inhibition of caspase-8 by IETD-fmk was more effective than the others tested. These results suggest that cleavage of c-Src during TGFb1-induced apoptosis is mediated by more than one caspase family member. In contrast, inhibitors specific for calpain (PD150606), cathepsin B (cathepsin inhibitor II) or cathepsin D (pepstatin A) did not affect TGF-b1-induced c-Src cleavage and apoptosis (Figure 1d ).
Inhibition of c-Src activity enhances TGF-b1-induced apoptosis, while activated c-Src confers resistance to TGF-b1-induced apoptosis We attempted to clarify whether activation of c-Src or the subsequent loss of c-Src activity accompanied by caspase-mediated cleavage is critical for TGF-b1-induced apoptosis. First, the effect of specific inhibitors of Src family kinases on the viability of FaO cells was determined (Figure 2a ). Both PP1 and PP2 slightly decreased cell viability in a dose-dependent manner, as determined by MTT assay. Furthermore, pretreatment with PP1 or PP2 accelerated TGF-b1-induced apoptosis. Next, we investigated the effect of dominant-negative (DN) c-Src on apoptosis. An expression vector encoding DN c-Src and the plasmid encoding green fluorescence protein (GFP) were co-transfected into FaO cells. Transfected cells were stained using Hoechst 33258 and apoptotic cells, characterized as those with fragmented nuclei, were then quantified in the GFP-positive cell populations. We found that DN c-Src expression induced apoptosis in a dose-dependent manner (Figure 2b ). Furthermore, TGF-b1 enhanced DN cSrc-stimulated apoptosis. In contrast, cell transfected Change in c-Src autophosphorylation during TGF-b1-induced apoptosis. Cells were treated with TGF-b1 for the indicated times, lysates prepared and subjected to Western blotting using a phospho-specific c-Src antibody to detect the active form of c-Src. (c) Degradation during TGF-b1-induced apoptosis. Western blotting using an antibody specific for the N-terminus of c-Src (GD11) and an antibody specific for the C-terminus (Src 2 Ab) was also performed to localize the site of c-Src cleavage. (d) Effect of specific protease inhibitors on TGF-b1-induced c-Src cleavage and apoptosis. Cells were pretreated with z-VAD-fmk (pan-caspase inhibitor), DEVDfmk (caspase-3 inhibitor), IETD-fmk (caspase-8 inhibitor), LEHDfmk (casapse-9 inhibitor), PD150606 (calpain inhibitor), cathepsin inhibitor II (cathepsin B inhibitor), or pepstatin A (cathepsin D inhibitor) at the indicated concentrations for 30 min, and then treated with TGF-b1 for the indicated times. c-Src cleavage was analysed by Western blot analysis using an anti-c-Src antibody (GD11). TGF-b1-induced apoptosis was assessed using the TUNEL assay. Values are the average of two independent experiments
Role of c-Src in TGF-b1-induced apoptosis SS Park et al with CA c-Src did not show any significant signs of apoptosis. Moreover, TGF-b1-induced apoptosis was alleviated by CA c-Src expression in a dose-dependent manner. Also in the established stable cell lines expressing CA c-Src in FaO cells (Figure 2c ), TGF-b1-induced apoptosis, as determined by MTT assay, was significantly suppressed (Figure 2d) .
TGF-b1-induced apoptosis is suppressed by Bcl-2 overexpression (Figure 3a) , as we have previously reported . We investigated the effect of Bcl-2 on TGF-b1-induced c-Src activation and its subsequent cleavage. Although TGF-b1-induced c-Src activation was not altered in Bcl-2-overexpressing cells, c-Src cleavage and downregulation of its activity below basal levels were blocked (Figure 3b ). These results demonstrate that antiapoptotic Bcl-2 acts upstream of caspase-mediated c-Src degradation. Taken together, the decrease in c-Src activity accompanied by caspasemediated degradation, rather than c-Src activation, may greatly contribute to TGF-b1-induced apoptosis.
Changes in the subcellular location of c-Src during TGF-b1-induced apoptosis
We examined how TGF-b1-induced changes in c-Src activity could contribute to apoptosis. First, we 
Changes in autophosphorylation of c-Src and its interaction with focal adhesion proteins during TGF-b1-induced apoptosis
Next, we attempted to investigate whether the changes in c-Src activity accompanying its subcellular translocation might play a role in TGF-b1-induced apoptosis. Paxillin and FAK, important for assembly of focal adhesions, have been reported to be phosphorylated by activated Src kinase (Schlaepfer and Hunter, 1996; Schaller, 2001 ). First, we examined whether the phosphorylation level of paxillin or FAK is altered depending on c-Src activity during TGF-b1-induced apoptosis. FaO cells were treated with TGF-b1 for 0, 8, and 24 h, and lysed, and the extracts were immunoprecipitated using an agaroseconjugated antiphospho-tyrosine antibody. Immunoblotting analysis of immunoprecipitates using antipaxillin antibody showed multiple paxillin bands were tyrosine phosphorylated 8 h after TGF-b1 treatment (Figure 5a ), the time of peak c-Src activity. After 24 h of TGF-b1 treatment, the extent of paxillin tyrosine phosphorylation was reduced. FAK tyrosine phosphorylation also transiently increased with a peak 8 h after TGF-b1 treatment ( Figure 5b ). Interestingly, FAK protein was cleaved into an 85 kDa fragment at 24 h, coincident with c-Src cleavage. Pretreatment with z-VAD-fmk completely abolished TGF-b1-induced FAK cleavage, demonstrating the involvement of caspases ( Figure 5c ). Next, we examined whether changes in c-Src activity affected its interaction with paxillin or FAK. After TGF-b1 treatment, cell extracts were subjected to immunoprecipitation using an anti-c-Src antibody and the immunoprecipitates were analysed by immunoblotting with antipaxillin ( Figure 6a ). Association of c-Src with paxillin was significantly increased after 8 h of TGF-b1 treatment, and then decreased by 24 h. This TGF-b1-induced transient association between paxillin and c-Src was also confirmed by Western blotting with anti-c-Src antibody after immunoprecipitation of cell extracts with an antipaxillin antibody. Association between c-Src and FAK also increased 8 h after TGF-b1 treatment, and at 24 h c-Src was still tightly associated with the 85 kDa degradation product of FAK (Figure 6b ). Immunoprecipitation analysis using anti-FAK antibody demonstrated that the 85 kDa degradation product of FAK was associated with not only p55 kDa degradation product of c-Src but also with intact 60 kDa c-Src. Subcellular fractionation analysis showed that the significant amount of the p85, the degradation product of FAK, was also translocated into nuclei at 24 h after TGF-b1 treatment ( Figure 6c ). These results suggest that the relocation of the complexes of inactivated c-Src and FAK from the foal adhesion sites into the nuclei may ultimately contribute to focal adhesion disassembly and apoptosis.
Active c-Src does not affect TGF-b1-induced phosphorylation of Smad2 and Smad3 but inhibits activation of JNK and caspases
Next, we examined the underlying mechanisms by which activated c-Src inhibits TGF-b1-induced apoptosis. Role of c-Src in TGF-b1-induced apoptosis SS Park et al Smad3 , JNK, p38 MAP kianse and caspases (Choi et al., 1998) have been implicated to play critical roles in TGF-b1-induced apoptotic signaling pathways. We first analysed phosphorylation of Smad2 and Smad3, an immediate early event in TGF-b1-induced signaling, in cells stably expressing active c-Src (CA c-Src/FaO) and control cells (pcDNA3/FaO). Analysis for Smad activation using the antibody specific for the phoshorylated form of Smad2 or Smad3 demonstrated that both Smad2 and Smad3 were phosphorylated in control cells (pcDNA3/ FaO cells) very early (from 30 min) after TGF-b1 treatment. While Smad2 phosphorylation was decreased after 8 h following TGF-b1 treatment, Smad3 phosphorylation was decreased after 4 h. Interestingly, overexpession of active c-Src did not affect this rapid phoshporylation of Smad2 and Smad3 in response to TGF-b1 (Figure 7a ). On the other hand, TGF-b1-induced activation of p38 or JNK was greatly suppressed in CA c-Src/FaO cells (Figure 7b ). Treatment of FaO cells with TGF-b1 resulted in cleavage of pro-caspase-2 (48 kDa) into the active caspase-2 (28 kDa), pro-caspase-7 (37 kDa) into the active caspase-7 subunit (20 kDa) and pro-caspase-3 into the active caspase-3 subunit (17 kDa) (Figure 7c ). However, CA c-Src overexpression inhibited TGF-b1-induced proteolytic processing of these caspases and degradation c-Src is activated in many human hepatoma cell lines resistant to TGF-b1
Next, we examined whether the cellular responses to TGF-b1 in a variety of human HCC cell lines might be associated with their endogenous c-Src activities. While TGF-b1 treatment greatly reduced the viability of FaO cells, as assessed by MTT assay, the same treatment significantly enhanced the viability of HepG2, SNU-354, SNU-475, PLC/PRF-5, and SNU-449 cells (Figure 8a ). Western blot analysis using an antibody specific for active c-Src showed that all of the HCC cell lines used in our study retained high endogenous c-Src activities, compared with that in FaO cell line (Figure 8b ). Interestingly, SNU-449 cells demonstrated an elevated c-Src activity despite their relatively low c-Src protein levels. After treatment with TGF-b1 for 24 h, the levels of phosphorylated c-Src in these HCC cells were also much higher than in FaO cells at the same time point. Taken together, these results suggest the possibility that responsiveness of HCC cells to the growth inhibitory effects by TGF-b1 may be controlled by their c-Src activity.
Discussion
Dysregulation of normal apoptosis is a critical event in development of various cancers including hepatoma. Since TGF-b is a potent antiproliferative cytokine for normal hepatocytes, obtaining the resistance to TGF-b1 in HCC may be one of the important factors in malignant transformation (Abou-Shady et al., 1999; de Caestecker et al., 2000) . Activation of c-Src in HCC is highly correlated with the indices of early stage Role of c-Src in TGF-b1-induced apoptosis SS Park et al phenotype (Ito et al., 2001) . In this study, we investigated the involvement of c-Src in the regulation of TGF-b1-induced apoptosis and possibly in hepatocarcinogenesis.
We found that addition of TGF-b1 to FaO cells resulted in transient activation of c-Src, which was followed by a significant inhibition of c-Src activity and its degradation during apoptosis. We present evidences suggesting inhibition of c-Src activity accompanying caspase-mediated cleavage is critical for TGF-b1-induced apoptosis; (a) c-Src is a target of caspases in TGFb1-induced apoptosis and c-Src activity is significantly decreased at the time of cleavage, (b) antiapoptotic Bcl-2 blocks TGF-b1-induced degradation of c-Src but not its activation, (c) inhibition of c-Src activity not only by the specific inhibitor but also expression of DN c-Src trigger apoptosis, (d) inhibition of c-Src activity enhances TGFb1-induced apoptosis, (e) expression of CA c-Src prevents TGF-b1-induced apoptosis.
Cell death is controlled by the integration of multiple positive and negative signals; when multiple effectors are activated in the same cell, the balance between conflicting signals determines cell survival or death. Therefore, early transient activation of c-Src may be one of the prosurvival signals activated TGF-b1 in FaO cells. However, during the later stages, failure to maintain c-Src activity, coupled with activation of various pro-apoptotic signals, may tip the balance towards cell death in response to TGF-b1.
In this study, we were interested in the interrelationship among c-Src activity, its subcellular localization, involvement in assembly/disassembly of focal adhesions, and downstream signal transduction cascades in the progression of TGF-b1-induced apoptosis. In the absence of TGF-b1, c-Src was diffusely distributed, and following activation by TGF-b1 c-Src was mainly found at the cytoplasmic membrane. However, at the time of cleavage, most of c-Src was observed in the nuclei of the cells undergoing apoptosis. Inhibition of caspase(s) activities by z-VAD-fmk blocked TGF-b1-induced translocation of c-Src into nuclei, suggesting that cleavage of c-Src precedes its nuclear translocation. Activated c-Src has been known to be translocated to the membrane as the result of interactions between its SH3 domain and targeting partners that link c-Src, and other adhesion proteins, to the actin cytoskeleton (Schwartzberg, 1998) . A candidate regulator of c-Src peripheral targeting is paxillin, a multidomain focal adhesion adaptor protein with a likely role in assembling peripheral focal adhesion complexes (Schaller, 2001 ). FAK is not only a potentially important c-Src substrate (Schlaepfer and Hunter, 1996) but also a c-Src effector that can lead to Src kinase activation (Schaller et al., 1994) . In our study, both phosphorylation and association of paxillin and FAK with c-Src was markedly increased during c-Src activation, suggesting the formation of focal adhesion complexes. However, activation of c-Src and its localization at the cytoplasmic membrane were not maintained for very long time, and c-Src lost its activity after 8 h of TGF-b1 treatment. Loss of cSrc activity might result in the reduction in phosphorylation of FAK and paxillin, leading to loss of its localization to the plasma membrane. And then, both cSrc and FAK might be vulnerable to degradation by cytosolic caspases that were initially activated by other apoptotic signaling pathways. Previously, cleavage of FAK at asp-772 by caspase-3-like proteases has been reported to generate the 85 kDa fragment of FAK, from which focal adhesion targeting (FAT) domain is separated (Wen et al., 1997; Jones et al., 2000) . This caspase-3-mediated FAK cleavage has been implicated in focal adhesion disassembly (Crouch et al., 1996; Gervais et al., 1998) and the N-terminal fragment of FAK has been shown to be translocated into the nuclei (Lobo and Zachary, 2000) . In our study, at later phase of TGF-b1-induced apoptosis complexes of c-Src and FAK relocated into nuclei, maintaining their tight association in spite of their degradation by caspases. Therefore, this translocation event of the complexes of c-Src and FAK from focal adhesion sites into nuclei may eventually contribute to focal adhesion disassembly.
We have previously shown that TGF-b1-induced activation of Smad3 , p38, JNK and caspases (Choi et al., 1998) are critical signaling pathways for TGF-b1-induced apoptosis. TGF-b signaling through the Smad pathway has been extensively characterized and is considered the canonical pathway. Receptor-regulated Smads (R-Smads), Smad2 and Smad3, are directly phosphorylated and activated by type I receptor. Phosphorylation occurs at Cterminal SSXS motifs and promotes the formation of heteromeric complexes with the common mediator Smad, Smad4. These Smads complexes translocate into the nucleus, where they regulate gene expression by directly interacting with resident DNA-binding proteins and by recruiting co-activators or co-repressors to the promoter (Massague, 1998; Wrana, 2000) . Many studies have shown that Smad3 is critical for TGF-b1-induced apoptosis in various cell types (Kanamaru et al., 2002; Wildey et al., 2003; Song et al., 2003; Kim et al., 2004) . TGF-b1-dependent apoptosis of rat FaO cells is also potently enhanced by expression of Smad3 and less efficiently by Smad2. Furthermore, TGF-b1-dependent apoptosis can be blocked by antisense Smad3 . In this study, overexpression of active c-Src in FaO cells blocked TGF-b1-induced apoptosis. However, TGF-b1-induced phosphorylation of Smad3, together with Smad2 phosphorylation, was not affected by overexpression of active c-Src, while TGF-b1-induced activation of p38, JNK and caspases was significantly suppressed by it. Therefore, c-Src activation may inhibit events occurring downstream of Smad3 phosphorylation but upstream of activation of p38, JNK and caspases during TGF-b1-induced signaling pathways. Taken together, activated c-Src in HCC may affect the ability of cancer cells to die in response TGFb1, a potent apoptotic inducer in hepatocytes, while inhibition of c-Src activity accompanying caspasemediated cleavage is critical for apoptosis in the cells sensitive to TGF-b1. Supporting this idea, our results showed that c-Src was activated in many HCC cell lines, which are resistant to the antiproliferating effect of TGF-b1. These results may explain how, in spite of high TGF-b1 expression in HCC, c-Src activation contributes to survival of hepatoma and their progression to malignancy. Previously, TGF-b1-signaling pathways in these HCC cells has been reported to be intact, since p21 and PAI-1, representative TGF-b1-responsive genes, are transcriptionally induced by TGF-b1 (Jong et al., 2002) . Therefore, we cannot exclude the possibility that activated c-Src may specifically inhibit apoptotic signaling pathways without altering TGF-b1-induced signaling pathways involved in gene expression. In conclusion, we hypothesize that deregulation of c-Src activity is a mechanism by which HCC resist the antiproliferative effects of TGF-b1, which in turn is likely to contribute to hepatocarcinogenesis.
Materials and methods
Reagents
Antibodies recognizing the amino terminal portion (amino acid 82-169) of c-Src (clone GD11) and recognizing phosphoSmad2 (06-829) were purchased form Upstate Biotechnology (Lake Placid, NY, USA). Antiphospho-Smad3 antibody to the peptide COOH-GSPSIRCSpSVpS (Wilkes et al., 2003) was a generous gift from Dr Edward B Leof (Mayo Clinic Cancer Center). Antibodies specific for the carboxy terminus of c-Src (SRC 2 Ab), against FAK (sc-557), and against caspase-2 (sc-625), were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody against caspase-7 (912431) was from Stressgen (Victoria, British Columbia). Antibody specific for paxillin (p13520) was from BD Pharmingen (San Diego, CA, USA). Antibodies specific for Smad2 (51-1300) and Smad3 (51-1500) were from Zymed (South San Francisco, CA, USA). Antibodies recognizing active c-Src autophosphorylated at tyr416, phosphorylated JNK, phosphorylated p38 and cleaved caspase-3 were from New England Biolabs (Beverly, MA, USA). z-VAD-fmk, DEVD-fmk, IETD-fmk, LEHD-fmk, PD 150606, pepstatin, cathepsin B inhibitor II, PP1 and PP2 were from Calbiochem-Novabiochem Corp. (San Diego, CA, USA). Enhanced chemiluminescence reagents were obtained from Amersham Corp. (Arlington Heights, IL, USA), and protein assay reagents were from Bio-Rad (Hercules, CA, USA). All other reagents and compounds were analytical grades.
Cell culture
FaO rat hepatoma cells were cultured in minimum essential medium a medium supplemented with 10% fetal bovine serum. Cells were split 1 day before treatment with TGF-b1. TGF-b1 (5 ng/ml) was added to 70-80% confluent cells. HepG2 cells were grown in DMEM supplemented with 10% fetal bovine serum (Gibco-BRL, Grand Island, NY, USA). Four welldefined human HCC cell lines were obtained from the Korean Cell LiIne Bank (Seoul, Korea) (Park et al., 1995; Lee et al., 1999) . These cells and PLC/PRF-5 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum.
TUNEL assay
FaO cells cultured on coverslips were treated with TGF-b1 for the indicated times and fixed with 4% paraformaldehyde (pH 7.4) for 10 min. The TUNEL assay of fragmented DNA was performed as recommended by the manufacturer (Boehringer Mannheim, Mannheim, Germany).
Western blot analysis of c-Src
A total of 1 Â 10 6 FaO cells were treated with TGF-b1 with or without a specific inhibitor, as indicated, and then washed once with ice-cold phosphate-buffered saline (PBS). Cells were lysed in boiling sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (62.5 mM Tris(pH 6.8), 1% SDS, 10% glycerol, and 5% b-mercaptoethanol), lysates sonicated, boiled for 5 min, subjected to SDS-PAGE, transferred to an Immobilon membrane (Millipore, Bedford, MA, USA) and a standard immunoblotting procedure was performed. For reprobing blots, membranes were deprobed in 0.2 N NaOH solution for 10 min, twice washed with the deionized water, equilibrated in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 20 min, and then blocked with 5% skim milk in TBST before probing with another antibody.
Immunocytochemistry
FaO cells were seeded onto coverslips and incubated for 1 day before TGF-b1 treatment. Cells were treated with TGF-b1 for the indicated times and fixed with 4% paraformaldehyde (pH 7.4) for 10 min at 41C, and permeabilized in 0.1% Triton X-100 in PBS for 5 min. Permeabilized cells were incubated for 45 min at room temperature with anti-Src antibody, washed with PBS three times, and then incubated with FITCconjugated goat anti-rabbit antibody (Molecular Probes, Eugene, OR, USA) for 30 min at room temperature. Nuclei were further stained for 10 min in 10 mg/ml Hoechst 33258 in PBS. Cells were subsequently mounted in fluorescent mounting medium (DAKO Corp., CA, USA) and observed using confocal laser scan microscope.
Immunoprecipitation and Western blotting of immunoprecipitated proteins After treatment with TGF-b1 for the indicated times, cells were washed with ice-cold PBS and lysed in lysis buffer (10 mM Tris pH 7.5, 1% Triton X-100, 10 mM MgCl 2 , 1 mM sodium vanadate, 5 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin; 0.5 ml/10 cm plate) on ice. The lysate was centrifuged (15 000 r.p.m., 15 min), and the supernatant was transferred to a new tube. For immunoprecipitation of cSrc, lysates (800 mg protein) were incubated with 1 mg of anti-cSrc antibody (GD11) for 3 h at 41C. The immunoprecipitates were collected with 20 ml of protein G-agarose for 1 h. For immunoprecipitation of tyrosine-phosphorylated proteins, lysates were incubated with 20 ml of agarose-conjugated antiphospho-tyrosine antibody (Upstate Biotechnology, Lake Placid, NY, USA) for 3 h at 41C. Immunoprecipitated proteins were resolved by SDS-PAGE and electrophoretically transferred onto Immobilon membrane (Millipore, Bedford, MA, USA). Immunoprecipitated/co-precipitated proteins were probed using antiphospho-tyrosine antibody (1 : 1000), antipaxillin (1 : 5000), anti-c-Src (GD11, 1 : 2000) and anti-FAK (1 : 500) antibodies.
Subcellular fractionation to detect the translocation of FAK
Cells were washed with PBS and incubated in 9 Â packed cell volume (PCV) of hypotonic buffer (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) for 15 min on ice with occasional gentle mixing. After addition of 1/2 Â PCV of 10% NP-40 into the mixture, cells were again incubated on ice for 5 min with occasional mixing. Cell extracts were centrifuged at 3000 r.p.m. for 10 min and supernatant was used as the cytosolic fraction. After washing with 10 Â PCV of hypotonic buffer, pellet was resuspended in 1 Â PCV of cold buffer (20 mM HEPES (pH 7.9), 20% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) and incubated on ice for 30 min with occasional gentle mixing. Lysates were centrifuged (13 000 r.p.m., 15 min) and the supernatant was used as the nuclear fraction. The respective fractions were processed for Western blotting of FAK.
Transient transfection with DN mutant and CA c-Src mutants
In total, 2 Â 10 6 cells were plated into 60 mm plates. After 24 h, cells were cotransfected with plasmids expressing DN c-Src (K296R/Y528F) or CA c-Src (Y529F), and the green fluorescent protein plasmid pEGFP-Vector (Clontech Laboratories Inc., Palo Alto, CA, USA) using Lipofectamine Plus reagent (Gibco BRL, Grand Island, NY, USA) following the manufacturer's instructions. DN c-Src mutant has two mutations, an arginine for lysine substitution (K296R) in the ATP binding pocket of the tyrosine kinase domain that abolishes phosphotransferase activity, and a phenylalanine for tyrosine substitution (Y528F) that abolishes phosphorylation, thereby preventing intramolecular interaction between the C-terminus and the SH2 domain of c-Src (Upstate Biotechnology, Lake Placid, NY, USA). CA c-Src contains a tyrosineto-phenylalanine substitution (Y529F), preventing normal downregulation and resulting in unregulated kinase activity (Upstate Biotechnology, Lake Placid, NY, USA). Following transfection, cells were left for 10 h, then washed three times with PBS, incubated for 8 min with 10 mg/ml Hoechst 33258 and observed using a fluorescence microscope. Apoptotic cells, characterized as those with condensed or fragmented nuclei, were then quantified in the GFP-positive cell populations. To observe the effect of TGF-b1, transfected cells were treated with TGF-b1 for 24 h following the 10 h interval mentioned above. These cells were also stained using Hoechst 33258 and the percentage of apoptotic cells was determined.
Establishment of the stable cell lines overexpressing the CA c-Src
FaO cells were transfected with the CA Src (Y529F) mutant, and stably transfected cells were selected using changes of fresh media containing G418 (500 mg/ml) for 3 weeks. FaO sublines stably transfected with an empty vector were used as a control. The expression of activated c-Src in selected cell lines was confirmed by Western blot analysis using antiphospho-specific c-Src antibody.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay Cell viability was assessed by measuring MTT reduction, an indicator of cell pyridine nucleotide redox state. Cells (1 Â 10 4 cells /well) were exposed to TGF-b1 for the indicated times, after which 10 ml of MTT solution (5 mg/ml in PBS) was added to each well, and plates were incubated for 3 h at 371C. After elution of the dye using dimethyl sulfoxide (Sigma, St Louis, MO, USA), absorbance at 540 nm was measured in a microtiter plate reader.
Abbreviations TGF-b1, transforming growth factor-b1; HCC, hepatocellular carcinoma; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling; SDS-PAGE, sodium dodecyl sulfate/polyacrylamide gel electrophoresis; DN, dominant negative; CA, constitutively active; GFP, green fluorescence protein.
